Please assess the completion status of the following clinical trial:

Trial Title: Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of chronic plaque psoriasis for at least 6 months~2. Age ≥ 18 years~3. Body surface area affected ≤ 10 percent~4. Presence of at least one pair of bilateral target lesions with an area of at least 20 cm2 per target lesion. The bilateral target lesions must be present in the same category of anatomical region (e.g., bilateral lower extremities, bilateral upper extremities or bilateral trunk).~Exclusion Criteria:~1. active or past history of erythrodermic psoriasis, guttate psoriasis, or pustular psoriasis~2. history of photosensitivity disorder~3. history of malignant melanoma~4. active, invasive non-melanoma skin carcinoma~5. Fitzpatrick Skin Type I~6. Subject has received ultraviolet B phototherapy or any topical anti-psoriatic therapy within two weeks prior to starting the study.~7. Subject has received systemic or topical psoralen-ultraviolet A photochemotherapy within four weeks prior to starting the study.~8. Subject has received biologic therapy within three months of starting the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Dosing (Type: ACTIVE_COMPARATOR): Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
- Plaque based dosing (Type: EXPERIMENTAL): Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).